BioTuesdays

Author - Melane Sampson

TCR2 Therapeutics Logo

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink raised its price target for TCR2 Therapeutics (NASDAQ:TCRR) to $41 from $28, citing positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing...

Venus-Concept-Logo

Stifel starts Venus Concepts at hold; PT $2.50

Stifel initiated coverage of Venus Concepts (NASDAQ:VERO) with a “hold” rating and price target of $2.50, citing “more work to be done in improving ARTAS,” the company’s robotic hair restoration system. The stock closed...

Prothena

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

Liquidia Logo

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

Curis Logo

HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

Syros-Logo

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

AVEO Pharmaceuticals Logo

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...